Study Details

Back to Search Results

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants with Overactive Bladder

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04562090

Astellas Study ID

The unique identification code given by the study sponsor.

178-MA-2295

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Urge to Urinate, Overactive Bladder Disease

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 Years - N/A

Sex

Female & Male

Product

mirabegron

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2021 - Mar 2022

Masking

None (Open Label)

Enrollment number

249

A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study With Mirabegron 50 mg and 25 mg in Chinese Participants with Overactive Bladder? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CN86001

Beijing, China

Site CN86020

Wuhan, China

Site CN86022

Wuxi, China

Site CN86013

Shanghai, China

Site CN86003

Lanzhou, China

Site CN86009

Guangzhou, China

Site CN86004

Beijing, China

Site CN86011

Wuhan, China

Site CN86010

Chengdu, China

Site CN86007

Zhengzhou, China

Site CN86014

Beijing, China

Site CN86012

Xi'an, China

Site CN86002

Suzhou, China

Site CN86018

Guangzhou, China

Site CN86021

Taiyuan, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo